

Helix BioMedix Expands Skin Care Product Distribution into Key Asian Markets through Agreement with RubyDerm Bio, Inc.

Bothell, Washington—March 11, 2010—Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, announced that the Company entered into an agreement with RubyDerm Bio, Inc. under which RubyDerm will assume responsibility, on an exclusive basis, for the distribution of certain of Helix BioMedix's branded prestige skin care products to spas, beauty stores, hospitals, clinics, physicians, and consumers in South Korea, China and Japan.

"RubyDerm Bio gives the Company access to three of the major Asian aesthetic and dermatology markets," said R. Stephen Beatty, President and CEO of Helix BioMedix. "We are delighted to expand our distribution through this partnership."

Jerry Jung, President and CEO of RubyDerm Bio, said, "Helix BioMedix has a proven peptide technology base for effective skin care backed by impressive science. We are happy to bring the Cerakine™ brand of skin health products to the South Korean, Chinese and Japanese aesthetic medical markets."

The four-year agreement includes certain minimum purchases and may be extended through mutual agreement.

About RubyDerm Bio, Inc.

RubyDerm Bio and its affiliate Mecca Life Sciences encompass four medical clinics, a clinical trials lab and two trading and marketing companies specializing in the aesthetic and dermatology market place. Corporate offices are located in Seoul, Korea with offices and distributors in markets throughout key Asian countries.

About Helix BioMedix, Inc.

Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of diverse bioactive peptides and patents covering six distinct classes and hundreds of thousands of peptide sequences. Core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology, leveraged through relationships with contract research organizations and peptide manufacturers. The company takes product development programs from the theoretical concept to a qualified skin care active ingredient fully validated as to efficacy and safety. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care and acne treatment as well as other topical anti-infective pharmaceuticals and wound healing applications. Striking™, Cerakine™, SmartPeptide™ and HB-AminoBright™ are trademarks of Helix BioMedix, Inc. More information about the company and its proprietary peptides may be found on the company's website at www.helixbiomedix.com.

For more information about becoming a distributor, please contact Robin Carmichael, Vice President of Marketing & Business Development at (425) 402-8400.

Forward Looking Statements

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to its potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, and continue developing marketable peptide-based products, and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in the company's reports and other filings with the Securities and Exchange Commission. Such filings are available on the company's website or at www.sec.gov. Readers

are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

Investor Contact:

Matt Kreps
Shelton Group Investor Relations
(972) 239-5119 X 125
mkreps@sheltongroup.com

Company Contact:

Robin Carmichael
VP Marketing & Business Development
(425) 402-8400
rcarmichael@helixbiomedix.com

#####